PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $18 | $17 | $14 |
| G&A Expenses | $0 | $4 | $4 | $11 |
| SG&A Expenses | $4 | $4 | $4 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $23 | $22 | $25 |
| Operating Income | -$23 | -$23 | -$22 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $2 | $2 | $2 |
| Pre-Tax Income | -$21 | -$21 | -$20 | -$23 |
| Tax Expense | -$0 | $0 | -$2 | $0 |
| Net Income | -$21 | -$21 | -$17 | -$23 |
| % Margin | – | – | – | – |
| EPS | -0.397 | -0.41 | -0.34 | 0.37 |
| % Growth | 3.1% | -20.6% | -191.9% | – |
| EPS Diluted | -0.397 | -0.41 | -0.34 | 0.37 |
| Weighted Avg Shares Out | 53 | 52 | 52 | 52 |
| Weighted Avg Shares Out Dil | 53 | 52 | 52 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$21 | -$21 | -$22 | -$25 |
| % Margin | – | – | – | – |